A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model-Reference-Cited by-同舟云学术

A combination of irinotecan/cisplatinum and irinotecan/temozolomide or tumor-targeting Salmonella typhimurium A1-R arrest doxorubicin- and temozolomide-resistant myxofibrosarcoma in a PDOX mouse model

Published:2018-11 Issue:3 Volume:505 Page:733-739
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Kiyuna Tasuku,Tome Yasunori,Murakami Takashi,Miyake Kentaro,Igarashi Kentaro,Kawaguchi Kei,Oshiro Hiromichi,Higuchi Takashi,Miyake Masuyo,Sugisawa Norihiko,Zhang Zhiying,Razmjooei Sahar,Wangsiricharoen Sintawat,Chmielowski Bartosz,Nelson Scott D.,Russell Tara A.,Dry Sarah M.,Li Yunfeng,Eckardt Mark A.,Singh Arun S.,Chawla Sant,Kanaya Fuminori,Eilber Fritz C.,Singh Shree Ram,Zhao Ming,Hoffman Robert M.

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference68 articles.

1. Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma;Lee;Ann. Surg Oncol.,2016

2. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution;Sanfilippo;Ann. Surg Oncol.,2011

3. Myxofibrosarcoma: a diagnostic pitfall;Castronovo;Rare Tumors,2013

4. The enigma of myxofibrosarcoma of the extremity;Mutter;Cancer,2012

5. Discoidin, CUB and LCCL domain-containing protein 2 (DCBLD2) is a novel biomarker of myxofibrosarcoma invasion identified by global protein expression profiling;Kikuta;Biochim. Biophys. Acta,2017

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing?;Cancers;2023-10-25

2. Progress in building clinically relevant patient‐derived tumor xenograft models for cancer research;Animal Models and Experimental Medicine;2023-09-07

3. Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives;Therapeutic Advances in Medical Oncology;2022-01

4. An mTOR and VEGFR inhibitor combination arrests a doxorubicin resistant lung metastatic osteosarcoma in a PDOX mouse model;Scientific Reports;2021-04-21

5. Development and validation of a prognostic nomogram for predicting the overall survival of myxofibrosarcoma patients: a large population-based study;Translational Cancer Research;2021-02